サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1073200

治療用ワクチンの世界市場：ワクチンの種類別 (抗原ワクチン、DNAワクチン、樹状細胞ワクチン)・ワクチンの組成方法別 (自己ワクチン、同種ワクチン)・治療の種類別 (単剤治療、併用治療)

Global Therapeutic Vaccines Market Distribution by Type of Vaccine (Antigen vaccine, DNA vaccine and Dendritic vaccine), Method of Vaccine Composition (Autologous vaccine and Allogeneic vaccine), Type of Therapy (Monotherapy and Combination Therapy),
出版日: | 発行: Roots Analysis | ページ情報: 英文 365 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
治療用ワクチンの世界市場：ワクチンの種類別 (抗原ワクチン、DNAワクチン、樹状細胞ワクチン)・ワクチンの組成方法別 (自己ワクチン、同種ワクチン)・治療の種類別 (単剤治療、併用治療)
出版日: 2022年05月06日
発行: Roots Analysis
ページ情報: 英文 365 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

病気の発生を予防するために設計され投与される予防ワクチンとは別に、研究者はすでに病気に感染している患者の苦痛を軽減することを目的とした治療用ワクチンを開発してきました。治療用ワクチンは予防用ワクチンほど有効ではありませんが、安全性、特異性、そして様々な臨床条件下での長期にわたる反応を実証しています。

当レポートでは、世界の治療用ワクチンの市場について分析し、製品の概要や市場の基本構造、パイプライン製品の概要や治験の進行状況、主要企業のプロファイル、主な資本取引・事業展開の動き、スタートアップの動向、現在・将来の市場機会、といった情報を取りまとめてお届けいたします。

本文中の図表サンプル

目次

第1章 序論

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • 分析概要
  • 治療用ワクチン：概要
    • ワクチンの分類：組成方法別
  • ワクチンの分類：作用機序別
    • 抗原ワクチン
    • 樹枝状ワクチン
    • DNAワクチン
    • ペプチドワクチン
  • 主な標的の兆候
    • がん
    • HIV感染症
    • HPV感染症
    • ヘルペス
  • ワクチンの臨床開発と承認
  • 結論

第4章 市場情勢

  • 分析概要
  • 治療用ワクチン：パイプライン分析
    • 開発段階別の分析
    • ワクチンの種類別の分析
    • ワクチンの種類別の分析（組成方法別）
    • 治療の種類別の分析
    • 標的疾患別の分析
    • 投与経路別の分析
    • 投与量別の分析
  • 治療用ワクチン：ワクチン開発企業の分析
    • 設立年別の分析
    • 企業規模別の分析
    • 本社所在地別び分析
    • 主要な開発企業
    • グリッド分析：開発段階別・企業規模別・本社所在地別

第5章 企業プロファイル

  • 分析概要
  • BioNTech
    • 企業概要
    • 財務情報
    • 治療用ワクチンポートのフォリオ
    • 最新動向と将来展望
  • Brii Biosciences
  • GlobeImmune
  • Immatics
  • Immune Response Biopharma
  • Immunitor
  • Inovio Pharmaceuticals
  • Moderna

第6章 治験の分析

  • 分析概要
  • 分析範囲・手法
  • 治療用ワクチン：治験分析
    • 治験登録年度別の分析
    • 治験登録年度別・登録患者集団別の分析
    • 治験段階別の分析
    • 採用状況別の分析
    • 研究デザイン別の分析
    • 治験の注力領域別分析
    • 標的疾患別の分析
    • スポンサー/コラボレーターの種類別の分析
    • 最も活動的な企業：登録された治験の件数分析
    • 登録された試験件数：地域別分析
    • 登録された患者集団：地域別分析

第7章 学術助成金の分析

  • 分析概要
  • 分析範囲・手法
  • 治療用ワクチン：学術助成金分析
    • 助成年度別の分析
    • 授与金額別の分析
    • 研究機関の運営主体別の分析
    • 助成期間別の分析
    • 運営主題別・助成期間別の分析
    • 助成金申請の種類別の分析
    • 助成金の目的別分析
    • 活動コード別の分析
    • 関与する研究部門別の分析
    • 受領者組織の種類別の分析
    • Word Cloud分析：新たな重点分野
    • 受領者組織の地理的分布
    • 人気のNIH部門：助成金の件数の分析
    • 著名なプログラムオフィサー：助成金の件数の分析
    • 人気のある受領組織：助成金の件数の分析

第8章 事業提携・協力

  • 分析概要
  • 事業提携モデル
  • 治療用ワクチン：事業提携・協力
    • 事業提携の年度別分析
    • 事業提携の種類別の分析
    • 事業提携の年度別・パートナーの種類別の分析
    • 事業提携の種類別・パートナーの種類別の分析
    • 重点分野別の分析
    • 治療領域別の分析
    • 最も活動的な企業：事業提携の件数の分析
    • 地域分析

第9章 スタートアップのヘルスインデックス

  • 分析概要
  • 治療用ワクチン市場のスタートアップ
    • 本社所在地別の分析
  • スタートアップのベンチマーク
    • サプライヤーの強さ別の分析
    • パイプラインの強度別の分析
    • パイプラインの成熟度別の分析
    • 金融投資別の分析
    • 提携活動別の分析
    • スタートアップのヘルスインデックス：ルーツ分析の視点

第10章 市場予測と機会分析

  • 分析概要
  • 予測手法と主要な仮定
  • 世界の治療用ワクチン市場 (2022年～2035年)
  • 世界の治療用ワクチン市場：ワクチンの種類別 (2022年～2035年)
  • 世界の治療用ワクチン市場：ワクチンの組成方法別 (2022年～2035年)
  • 世界の治療用ワクチン市場：治療の種類別 (2022年～2035年)
  • 世界の治療用ワクチン市場：標的疾患別 (2022年～2035年)
  • 世界の治療用ワクチン市場：投与経路別 (2022年～2035年)
  • 世界の治療用ワクチン市場：地域別 (2022年～2035年)
    • 米国の治療用ワクチン市場 (2022年～2035年)
    • カナダの治療用ワクチン市場 (2022年～2035年)
    • 英国の治療用ワクチン市場 (2022年～2035年)
    • ドイツの治療用ワクチン市場 (2022年～2035年)
    • フランスの治療用ワクチン市場 (2022年～2035年)
    • イタリアの治療用ワクチン市場 (2022年～2035年)
    • スペインの治療用ワクチン市場 (2022年～2035年)
    • オーストラリアの治療用ワクチン市場 (2022年～2035年)
    • 日本の治療用ワクチン市場 (2022年～2035年)
    • 韓国の治療用ワクチン市場 (2022年～2035年)
    • ブラジルの治療用ワクチン市場 (2022年～2035年)
    • イスラエルの治療用ワクチン市場 (2022年～2035年)
  • 世界の治療用ワクチン市場：個別製品の売上予測 (2022年～2035年)
    • ASP0113
    • Copaxone
    • Galinpepimut-S
    • Hepcortespenlisimut-L
    • ICT-107
    • IR103
    • MGN1703
    • Neuronata-R
    • OncoVax
    • OSE2101
    • Provenge
    • REMUNE
    • RIAVAX
    • V503
    • V7
    • VGX-3100
    • Vigil

第11章 ケーススタディ：世界の予防ワクチン

  • 分析概要
  • 予防ワクチン：市場情勢
    • 市販ワクチンの情勢
    • ワクチンの情勢：治験段階別
    • 開発段階別の分析
    • 投与経路別の分析
    • ワクチンAPIの種類別の分析
    • 剤形別分の析
    • 標的疾患別の分析
    • 主要な業界企業：臨床開発におけるワクチンの件数の分析
    • 主要な非業界企業：臨床開発におけるワクチンの件数の分析

第12章 ケーススタディ：ワクチンの受託製造市場

  • 分析概要
  • ワクチン受託製造企業：全体的な市場情勢
    • 設立年度別の分析
    • 企業の規模別・立地別の分析
    • 地域別の分析
    • 提供サービスの種類別の分析
    • 運用規模別の分析
    • 使用した発現系の種類別の分析
    • 製造されたワクチンの種類別の分析

第13章 結論

第14章 付録1：集計データ

第15章 付録2：企業・組織の一覧

目次

Title:
Global Therapeutic Vaccines
Market Distribution by Type of Vaccine (Antigen vaccine, DNA vaccine and Dendritic vaccine), Method of Vaccine Composition (Autologous vaccine and Allogeneic vaccine), Type of Therapy (Monotherapy and Combination Therapy), Target Disease Indication (Cervical Cancer, Ewing Sarcoma, Glioblastoma, HIV Infection, Ovarian cancer, Prostate Cancer, Tuberculosis, Others), Route of Administration (Intravenous, Intradermal, Subcutaneous, Oral and Others) and Key Geographical Regions (North America, Europe, Asia-Pacific, Middle East and North Africa and rest of the world): Industry Trends and Global Forecasts, 2022-2035.

Example Insights:

Overview

Unlike the prophylactic vaccines that are designed and administered as a precautionary measure to prevent the occurrence of a disease, researchers have developed therapeutic vaccines intended to alleviate the suffering of patients already infected with the disease. Therapeutic vaccines are not as efficacious as prophylactic vaccines; however, they demonstrate safety, specificity and a long-lasting response across various clinical conditions. These vaccines help the immune system in recognizing a foreign agent and are primarily being developed for viral infections and different types of cancer. Additionally, individuals who are affected with chronic infections but cannot produce enough efficient antibodies can be administered such vaccines. Currently, six therapeutic vaccines are commercially available, including Imlygic®, Provenge® and Tice® which have recently been approved for treatment of melanoma, prostate cancer and bladder cancer, respectively; in addition, over 350 vaccines are under development for various oncological, infectious, hepatological, neurological and autoimmune disorders.

Extensive research is being conducted to improve the overall stability of these therapeutic formulations and a variety of adjuvants (substances with an innate potential to augment an immune response) have been discovered for the development of more versatile vaccine formulations. Further, researchers are also investigating the potential of these vaccines against other chronic disease conditions, including hypertension and autoimmune disorders. Over the last few years, this segment of industry has witnessed substantial partnership activity and investment from various private and public sector investors / investment funds, which have extended financial support to the organizations engaged in R&D. Driven by encouraging clinical trial results, increasing adoption of therapeutic vaccines for treating various clinical conditions and investment in R&D, the therapeutic vaccines market is poised to witness noteworthy growth in the foreseen future.

Scope of the Report

The "Global Therapeutic Vaccines Market, 2022-2035" report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution and future opportunities associated with the therapeutic vaccines market. The study underlines an in-depth analysis, highlighting the key drivers and the market trends related to this evolving segment of the pharmaceutical industry. Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape of therapeutic vaccines, based on several relevant parameters, such as phase of development (clinical and preclinical) of lead candidates, type of vaccine (antigen vaccine, dendritic vaccine, DNA vaccine and peptide vaccine) , type of vaccine by method of composition (autologous vaccine and allogeneic vaccine) , type of therapy (monotherapy and combination therapy), target disease indication and route of administration (intramuscular, intranasal, oral, intradermal, subcutaneous, intravenous and others) and dosing frequency. It also includes a list of players developing therapeutic vaccines along with information on their year of establishment, company size and location of headquarters.
  • Elaborate profiles of key players engaged in the development of therapeutic vaccines, based across North America, Europe and Asia Pacific. Each profile features a brief overview of the company, its financial information (if available) , details on its clinical-stage vaccine candidates, recent developments and an informed future outlook.
  • A detailed analysis of completed, ongoing and planned clinical trials of various therapeutic vaccines, based on important parameters, such as trial registration year, phase of development, trial recruitment status, study design, trial focus area, target disease indication(s), type of sponsor / collaborator, leading industry sponsors / collaborators (in terms of number of trials conducted), number of patients enrolled and regional distribution.
  • An in-depth analysis of grants that have been awarded to various research institutes for research related to therapeutic vaccines, during the period, 2016-2022, on the basis of different parameters, such as year of grant award, amount awarded, administering institute center, support period, type of grant application, purpose of grant award, activity code, focus area, study section involved, type of recipient organization and focus area. In addition, it highlights the geographical distribution of recipient organizations, popular NIH departments, prominent program officers, and popular recipient organizations.
  • An analysis of the partnerships that have been established in this domain since 2016, covering instances of product development and / or commercialization agreements, R&D collaborations, licensing agreements, mergers and acquisitions, clinical trial agreements, and other relevant deals.
  • An analysis of the various start-ups engaged in the field of therapeutic vaccines, based on relevant parameters, such as number of candidates in discovery, preclinical and clinical phases of development, amount raised in different funding instances and number of partnerships established.
  • A case study on preventive vaccines, along with information on marketed as well as clinical-stage candidates, based on parameters, such as phase of development, route of administration (intramuscular, subcutaneous, oral, intranasal, intradermal and others), type of vaccine API (live attenuated vaccine, inactivated vaccine, conjugate vaccine, subunit vaccine, toxoid vaccine and others), dosage form (ready to use liquid, lyophilized powder, nasal spray, capsule, and tablet) and target disease indication.
  • A case study on contract manufacturing for vaccines, featuring a comprehensive list of active CMOs and analyses based on a number of parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial) , geographical location, number of vaccine manufacturing facilities, types of services offered (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings), type of expression systems used for vaccine production (mammalian, microbial and others) and type of vaccine manufactured.

One of the key objectives of the report was to estimate the existing market size and future growth opportunity associated with therapeutic vaccines market in the mid to long term. Based on parameters, such as adoption rates and expected prices variations for these products, we have developed informed estimates on the likely evolution of the market for the period 2022-2035.

Our year-wise projections of the current and forecasted opportunity within the therapeutic vaccines market, have further been segmented across different types of vaccines (antigen vaccine, dendritic vaccine, DNA vaccine and peptide vaccine), types of vaccines by method of composition (autologous and allogeneic vaccine), types of therapies (monotherapy and combination), target disease indications, routes of administration (intramuscular, subcutaneous, oral, intranasal, intradermal and others) and key geographical regions (North America, Europe and Asia Pacific).

In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in the report were influenced by discussions held with senior representatives in the industry. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Who are the leading industry players involved in developing therapeutic vaccines?
  • What are the key therapeutic areas for which therapeutic vaccines are being / have been developed?
  • What are the prevalent trends within competitive landscape of therapeutic vaccines?
  • Which geographies are the most active in conducting clinical trials related to therapeutic vaccines?
  • Which are the leading funding organizations providing grants for therapeutic vaccines?
  • What kind of partnership models are commonly adopted by industry and non-industry stakeholders?
  • What are the different initiatives undertaken by start-up players for the development of therapeutic vaccines in the recent past?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured during our research. It offers a high-level view on the current state of the therapeutic vaccines market and its likely evolution in the mid to long term.

Chapter 3 provides a general introduction to therapeutic vaccines, including information on their types, characterized by the method of composition and mechanism of action. Additionally, the chapter provides information on the various disease indications for which therapeutic vaccines are being investigated / developed. Further, the chapter features a brief overview of clinical development and approval processes for vaccines and the future perspectives.

Chapter 4 provides a detailed assessment of the current market landscape of over 300 therapeutic vaccines that are currently being evaluated across different stages of development. It features a comprehensive analysis of the pipeline molecules based on several relevant parameters, such as, phase of development (clinical and preclinical) , type of vaccine (antigen vaccine, dendritic vaccine, DNA vaccine, peptide vaccine), type of vaccine by method of composition (autologous vaccine, allogeneic vaccine), type of therapy (monotherapy and combination therapy), dosage (weekly, biweekly, monthly, bimonthly, triweekly), target disease indication, route of administration (intramuscular, intranasal, oral, intradermal, subcutaneous, intravenous and others) and dosage frequency.

Chapter 5 includes detailed profiles of key players engaged in the development of therapeutic vaccines, based across North America, Europe and Asia Pacific. Each profile features a brief overview of the company, its financial information (if available) , details on its clinical-stage vaccines candidates, recent developments and an informed future outlook.

Chapter 6 provides information on more than 790 completed, ongoing and planned clinical trials of therapeutic vaccines, based on different parameters, such as trial registration year, trial phase, trial recruitment status, study design, trial focus area, target disease indication(s), type of sponsor / collaborator, leading industry sponsors / collaborators (in terms of number of trials conducted), enrolled patients population and regional distribution.

Chapter 7 provides an in-depth analysis of more than 500 grants that have been awarded to various research institutes for research related to therapeutic vaccines, during the period, 2016-2022, on the basis of different parameters, such year of grant award, amount awarded, administering institute center, support period, type of grant application, purpose of grant award, activity code, focus area, study section involved, type of recipient organizations and focus area. In addition, it highlights the geographical distribution of recipient organizations, popular NIH departments, prominent program officers, and popular recipient organizations.

Chapter 8 provides a detailed analysis of the recent collaborations established since 2016. It includes analysis based on relevant parameters, such as year of agreement, type of agreement, therapeutic area, type of partner and regional distribution of partnerships.

Chapter 9 features an analysis of the various start-ups engaged in development of therapeutic vaccines, based on relevant parameters, such as number of candidates in discovery, preclinical and clinical phases of development, number of partnerships, number of patents, amount raised, number of investors, types of funding and number of deals inked.

Chapter 10 includes an analysis of the big pharma players engaged in the field of therapeutic vaccines, featuring different insightful representations, such as spider web analysis, Harvey ball analysis and wind rose chart, based on parameters, such as number of vaccines under development, type of vaccine, type of vaccine (by method of composition), type of therapy, number of therapeutic areas, number of partnerships, and years of experience.

Chapter 11 presents an insightful market forecast analysis, highlighting the likely growth of the therapeutic vaccines market, till 2035. In order to provide a detailed future outlook, our projections have been segmented across across different types of vaccines (antigen vaccine, dendritic vaccine, DNA vaccine and peptide vaccine), types of vaccines by method of composition (autologous vaccine and allogeneic vaccine), types of therapies (monotherapy and combination), target disease indications, routes of administration (intramuscular, subcutaneous, oral, intranasal, intradermal and others) and key geographical regions (North America, Europe and Asia Pacific).

Chapter 12 features a case study of preventive vaccines, along with information on marketed as well as clinical-stage candidates, based on parameters, such as phase of development, route of administration (intramuscular, subcutaneous, oral, intranasal, intradermal and others), type of vaccine API (live attenuated vaccine, inactivated vaccine, conjugate vaccine, subunit vaccine, toxoid vaccine and others), dosage form (ready to use liquid, lyophilized powder, nasal spray, capsule, and tablet) and target disease indication.

Chapter 13 presents a case study on contract manufacturing for vaccines, featuring a comprehensive list of active CMOs and analyses based on a number of parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), geographical location, number of vaccine manufacturing facilities, types of services offered (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings), type of expression systems used for vaccine production (mammalian, microbial and others) and type of vaccine manufactured.

Chapter 14 is a summary of the overall report, which presents insights on the contemporary market trends and the likely evolution of the therapeutics vaccines market.

Chapter 15 is an appendix that contains tabulated data and numbers for all the figures in the report.

Chapter 16 is an appendix that provides the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Introduction to Therapeutic Vaccines
    • 3.2.1. Classification of Vaccines by Method of Composition
      • 3.2.1.1. Autologous Vaccines
      • 3.2.1.2. Allogeneic Vaccines
  • 3.3. Classification of Vaccines by Mechanism of Action
    • 3.3.1. Antigen Vaccines
    • 3.3.2. Dendritic Vaccines
    • 3.3.3. DNA Vaccines
    • 3.3.4. Peptide Vaccines
  • 3.4 Key Target Indications
    • 3.4.1. Cancer
    • 3.4.2. HIV Infection
    • 3.4.3. HPV Infection
    • 3.4.4. Herpes
  • 3.5. Clinical Development and Approval of Vaccines
  • 3.6. Concluding Remarks

4. MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Therapeutic Vaccines: Pipeline Analysis
    • 4.2.1. Analysis by Phase of Development
    • 4.2.2. Analysis by Type of Vaccine
    • 4.2.3. Analysis by Type of Vaccine (by Method of Composition)
    • 4.2.4. Analysis by Type of Therapy
    • 4.2.5. Analysis by Target Disease Indication
    • 4.2.6. Analysis by Route of Administration
    • 4.2.7. Analysis by Dosage
  • 4.3. Therapeutic Vaccines: Analysis by Vaccine Developers
    • 4.3.1. Analysis by Year of Establishment
    • 4.3.2. Analysis by Company Size
    • 4.3.3. Analysis by Location of Headquarters
    • 4.3.4. Leading Developers
    • 4.3.5. Grid Analysis: Distribution by Phase of Development, Company Size and Location of Headquarters

5. COMPANY PROFILES

  • 5.1. Chapter Overview
  • 5.2. BioNTech
    • 5.2.1. Company Overview
    • 5.2.2. Financial Information
    • 5.2.3. Therapeutic Vaccines Portfolio
    • 5.2.4. Recent Developments and Future Outlook
  • 5.3 Brii Biosciences
    • 5.3.1. Company Overview
    • 5.3.2. Financial Information
    • 5.3.3. Therapeutic Vaccines Portfolio
    • 5.3.4. Recent Developments and Future Outlook
  • 5.4 GlobeImmune
    • 5.4.1. Company Overview
    • 5.4.2. Financial Information
    • 5.4.3. Therapeutic Vaccines Portfolio
    • 5.4.4. Recent Developments and Future Outlook
  • 5.5 Immatics
    • 5.5.1. Company Overview
    • 5.5.2. Financial Information
    • 5.5.3. Therapeutic Vaccines Portfolio
    • 5.5.4. Recent Developments and Future Outlook
  • 5.6. Immune Response Biopharma
    • 5.6.1. Company Overview
    • 5.6.2. Financial Information
    • 5.6.3. Therapeutic Vaccines Portfolio
    • 5.6.4. Recent Developments and Future Outlook
  • 5.7. Immunitor
    • 5.7.1. Company Overview
    • 5.7.2. Financial Information
    • 5.7.3. Therapeutic Vaccines Portfolio
    • 5.7.4. Recent Developments and Future Outlook
  • 5.8. Inovio Pharmaceuticals
    • 5.8.1. Company Overview
    • 5.8.2. Financial Information
    • 5.8.3. Therapeutic Vaccines Portfolio
    • 5.8.4. Recent Developments and Future Outlook
  • 5.9. Moderna
    • 5.9.1. Company Overview
    • 5.9.2. Financial Information
    • 5.9.3. Therapeutic Vaccines Portfolio
    • 5.9.4. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS

  • 6.1. Chapter Overview
  • 6.2. Scope and Methodology
  • 6.3. Therapeutic Vaccines: Clinical Trial Analysis
    • 6.3.1. Analysis by Trial Registration Year
    • 6.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
    • 6.3.3. Analysis by Trial Phase
    • 6.3.4. Analysis by Trial Recruitment Status
    • 6.3.5. Analysis by Study Design
    • 6.3.6. Analysis by Trial Focus Area
    • 6.3.7. Analysis by Target Disease Indication
    • 6.3.8. Analysis by Type of Sponsor / Collaborator
    • 6.3.9. Most Active Players: Analysis by Number of Registered Trials
    • 6.3.10. Geographical Analysis by Number of Registered Trials
    • 6.3.11. Geographical Analysis by Enrolled Patient Population

7. ACADEMIC GRANT ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Scope and Methodology
  • 7.3. Therapeutic Vaccines: Academic Grant Analysis
    • 7.3.1. Analysis by Year of Grant Award
    • 7.3.2. Analysis by Amount Awarded
    • 7.3.3. Analysis by Administering Institute Center
    • 7.3.4. Analysis by Support Period
    • 7.3.5. Analysis by Administering Institute Center and Support Period
    • 7.3.6. Analysis by Type of Grant Application
    • 7.3.7. Analysis by Purpose of Grant Award
    • 7.3.8. Analysis by Activity Code
    • 7.3.9. Analysis by Study Section Involved
    • 7.3.10. Analysis by Type of Recipient Organization
    • 7.3.11. Word Cloud Analysis: Emerging Focus Areas
    • 7.3.12. Geographical Distribution of Recipient Organizations
    • 7.3.13. Popular NIH Departments: Analysis by Number of Grants
    • 7.3.14. Prominent Program Officers: Analysis by Number of Grants
    • 7.3.15. Popular Recipient Organizations: Analysis by Number of Grants

8. PARTNERSHIPS AND COLLABORATIONS

  • 8.1. Chapter Overview
  • 8.2. Partnership Models
  • 8.3. Therapeutic Vaccines: Partnerships and Collaborations
    • 8.3.1. Analysis by Year of Partnership
    • 8.3.2. Analysis by Type of Partnership
    • 8.3.3. Analysis by Year of Partnership and Type of Partner
    • 8.3.4. Analysis by Type of Partnership and Type of Partner
    • 8.3.5. Analysis by Focus Area
    • 8.3.6. Analysis by Therapeutic Area
    • 8.3.7. Most Active Players: Analysis by Number of Partnerships
    • 8.3.8. Regional Analysis
      • 8.3.8.1. Intercontinental and Intracontinental Agreements

9. START-UP HEALTH INDEXING

  • 9.1. Chapter Overview
  • 9.2. Start-ups in Therapeutic Vaccines Market
    • 9.2.1. Analysis by Location of Headquarters
  • 9.3. Benchmarking of Start-ups
    • 9.3.1. Analysis by Supplier Strength
    • 9.3.2. Analysis by Pipeline Strength
    • 9.3.3. Analysis by Pipeline Maturity
    • 9.3.4. Analysis by Financial Investment
    • 9.3.5. Analysis by Partnership Activity
    • 9.3.6. Start-ups Health Indexing: Roots Analysis Perspective

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Forecast Methodology and Key Assumptions
  • 10.3. Global Therapeutic Vaccines Market, 2022-2035
  • 10.4. Global Therapeutic Vaccines Market, 2022-2035: Distribution by Type of Vaccine
  • 10.5. Global Therapeutic Vaccines Market, 2022-2035: Distribution by Method of Vaccine Composition
  • 10.6. Global Therapeutic Vaccines Market, 2022-2035: Distribution by Type of Therapy
  • 10.7. Global Therapeutic Vaccines Market, 2022-2035: Distribution by Target Disease Indication
  • 10.8. Global Therapeutic Vaccines Market, 2022-2035: Distribution by Route of Administration
  • 10.9. Global Therapeutic Vaccines Market, 2022-2035: Geographical Distribution
    • 10.9.1. Therapeutic Vaccines Market in US, 2022-2035
    • 10.9.2. Therapeutic Vaccines Market in Canada, 2022-2035
    • 10.9.3. Therapeutic Vaccines Market in UK, 2022-2035
    • 10.9.4. Therapeutic Vaccines Market in Germany, 2022-2035
    • 10.9.5. Therapeutic Vaccines Market in France, 2022-2035
    • 10.9.6. Therapeutic Vaccines Market in Italy, 2022-2035
    • 10.9.7. Therapeutic Vaccines Market in Spain, 2022-2035
    • 10.9.8. Therapeutic Vaccines Market in Australia, 2022-2035
    • 10.9.9. Therapeutic Vaccines Market in Japan, 2022-2035
    • 10.9.10. Therapeutic Vaccines Market in Korea, 2022-2035
    • 10.9.11. Therapeutic Vaccines Market in Brazil, 2022-2035
    • 10.9.12. Therapeutic Vaccines Market in Israel, 2022-2035
  • 10.10. Global Therapeutic Vaccines Market, 2022-2035: Individual Product Sales Forecast
    • 10.10.1. ASP0113
      • 10.10.1.1. Target Patient Population
      • 10.10.1.2. Sales Forecast
    • 10.10.2. Copaxone
      • 10.10.2.1. Target Patient Population
      • 10.10.2.2. Sales Forecast
    • 10.10.3. Galinpepimut-S
      • 10.10.3.1. Target Patient Population
      • 10.10.3.2. Sales Forecast
    • 10.10.4. Hepcortespenlisimut-L
      • 10.10.4.1. Target Patient Population
      • 10.10.4.2. Sales Forecast
    • 10.10.5. ICT-107
      • 10.10.5.1. Target Patient Population
      • 10.10.5.2. Sales Forecast
    • 10.10.6. IR103
      • 10.10.6.1. Target Patient Population
      • 10.10.6.2. Sales Forecast
    • 10.10.7. MGN1703
      • 10.10.7.1. Target Patient Population
      • 10.10.7.2. Sales Forecast
    • 10.10.8. Neuronata-R
      • 10.10.8.1. Target Patient Population
      • 10.10.8.2. Sales Forecast
    • 10.10.9. OncoVax
      • 10.10.9.1. Target Patient Population
      • 10.10.9.2. Sales Forecast
    • 10.10.10. OSE2101
      • 10.10.10.1. Target Patient Population
      • 10.10.10.2. Sales Forecast
    • 10.10.11. Provenge
      • 10.10.11.1. Target Patient Population
      • 10.10.11.2. Sales Forecast
    • 10.10.12. REMUNE
      • 10.10.12.1. Target Patient Population
      • 10.10.12.2. Sales Forecast
    • 10.10.13. RIAVAX
      • 10.10.13.1. Target Patient Population
      • 10.10.13.2. Sales Forecast
    • 10.10.14. V503
      • 10.10.14.1. Target Patient Population
      • 10.10.14.2. Sales Forecast
    • 10.10.15. V7
      • 10.10.15.1. Target Patient Population
      • 10.10.15.2. Sales Forecast
    • 10.10.16. VGX-3100
      • 10.10.16.1. Target Patient Population
      • 10.10.16.2. Sales Forecast
    • 10.10.17. Vigil
      • 10.10.17.1. Target Patient Population
      • 10.10.17.2. Sales Forecast

11. CASE STUDY: GLOBAL PREVENTIVE VACCINES

  • 11.1. Chapter Overview
  • 11.2. Preventive Vaccines: Overall Market Landscape
    • 11.2.1. Marketed Vaccines Landscape
    • 11.2.2. Clinical-Stage Vaccines Landscape
    • 11.2.3. Analysis by Phase of Development
    • 11.2.4. Analysis by Route of Administration
    • 11.2.5. Analysis by Type of Vaccine API
    • 11.2.6. Analysis by Dosage Form
    • 11.2.7. Analysis by Target Disease Indication
    • 11.2.8. Key Industry Players: Analysis by Number of Vaccines in Clinical Development
    • 11.2.9. Key Non-Industry Players: Analysis by Number of Vaccines in Clinical Development

12. CASE STUDY: VACCINE CONTRACT MANUFACTURING MARKET

  • 12.1 Chapter Overview
  • 12.2. Vaccine Contract Manufacturers: Overall Market Landscape
    • 12.2.1 Analysis by Year of Establishment
    • 12.2.2. Analysis by Company Size and Geographical Location
    • 12.2.3. Analysis by Geography
    • 12.2.4. Analysis by Type of Service(s) Offered
    • 12.2.5. Analysis by Scale of Operation
    • 12.2.6. Analysis by Type of Expression System(s) Used
    • 12.2.7. Analysis by Type of Vaccines Manufactured

13. CONCLUDING REMARKS

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List OfFigures

  • Figure 3.1 Difference between Preventive Vaccines and Therapeutic Vaccines
  • Figure 3.2 Different Routes of Vaccine Administration
  • Figure 4.1 Therapeutic Vaccines: Distribution by Phase of Development
  • Figure 4.2 Therapeutic Vaccines: Distribution by Type of Vaccine
  • Figure 4.3 Therapeutic Vaccines: Distribution by Type of Vaccine (by Method of Composition)
  • Figure 4.4 Therapeutic Vaccines: Distribution by Type of Therapy
  • Figure 4.5 Therapeutic Vaccines: Distribution by Target Disease Indication
  • Figure 4.6 Therapeutic Vaccines: Distribution by Route of Administration
  • Figure 4.7 Therapeutic Vaccines: Distribution by Dosage
  • Figure 4.8 Therapeutic Vaccines Developers: Distribution by Type of Developers
  • Figure 4.9 Therapeutic Vaccines Developers: Distribution by Year of Establishment
  • Figure 4.10 Therapeutic Vaccines Developers: Distribution by Company Size
  • Figure 4.11 Therapeutic Vaccines Developers: Distribution by Location of Headquarters
  • Figure 4.12 Leading Developers
  • Figure 4.13 Grid Analysis: Distribution by Phase of Development, Company Size and Location of Headquarters
  • Figure 5.1 BioNTech: Annual Revenues, 2016-2021 (USD Million)
  • Figure 5.2 Brii Biosciences: Annual Revenues, 2016-2021 (USD Million)
  • Figure 5.3 GlobeImmune: Annual Revenues, 2016-2021 (USD Million)
  • Figure 5.4 Immatics: Annual Revenues, 2016-2021 (USD Million)
  • Figure 5.5 Immune Response Biopharma: Annual Revenues, 2016-2021 (USD Million)
  • Figure 5.6 Inovio Pharmaceuticals: Annual Revenues, 2016-2021 (USD Million)
  • Figure 5.7 Moderna: Annual Revenues, 2016-2021 (USD Million)
  • Figure 6.1 Clinical Trial Analysis: Scope and Methodology
  • Figure 6.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2010-2022
  • Figure 6.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2010-2022
  • Figure 6.4 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 6.5 Clinical Trial Analysis: Distribution by Trial Recruitment Status
  • Figure 6.6 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
  • Figure 6.7 Clinical Trial Analysis: Distribution by Study Design
  • Figure 6.8 Clinical Trial Analysis: Distribution by Trial Focus Area
  • Figure 6.9 Clinical Trial Analysis: Distribution by Target Disease Indication
  • Figure 6.10 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 6.11 Most Active Players: Distribution by Number of Registered Trials
  • Figure 6.12 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
  • Figure 6.13 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
  • Figure 7.1 Grant Analysis: Cumulative Year-wise Trend, 2016-2022
  • Figure 7.2 Grant Analysis: Cumulative Distribution by Amount Awarded (USD Million) 2016-2022
  • Figure 7.3 Grant Analysis: Distribution by Administering Institute Center
  • Figure 7.4 Grant Analysis: Distribution by Support Period
  • Figure 7.5 Grant Analysis: Distribution by Administering Institute Center and Support Period
  • Figure 7.6 Grant Analysis: Distribution by Type of Grant Application
  • Figure 7.7 Grant Analysis: Distribution by Purpose of Grant Award
  • Figure 7.8 Grant Analysis: Distribution by Activity Code
  • Figure 7.9 Grant Analysis: Distribution by Study Section Involved
  • Figure 7.10 Grant Analysis: Distribution by Type of Recipient Organization
  • Figure 7.11 Word Cloud Analysis: Emerging Focus Areas
  • Figure 7.12 Grant Analysis: Geographical Distribution of Recipient Organizations
  • Figure 7.13 Popular NIH Departments: Distribution by Number of Grants
  • Figure 7.14 Prominent Program Officers: Distribution by Number of Grants
  • Figure 7.15 Popular Recipient Organizations: Distribution by Number of Grants
  • Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2022
  • Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 8.3 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
  • Figure 8.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
  • Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Figure 8.6 Partnerships and Collaborations: Distribution by Focus Areas
  • Figure 8.7 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Figure 8.8 Most Active Players: Distribution by Number of Partnerships
  • Figure 8.9 Partnerships and Collaborations: Regional Distribution
  • Figure 8.9.1 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Figure 9.1 Startup-Health Indexing: Distribution by Location of Headquarters
  • Figure 9.2 Startup-Health Indexing: Distribution by Supplier Strength
  • Figure 9.3 Startup-Health Indexing: Distribution by Pipeline Strength
  • Figure 9.4 Startup-Health Indexing: Distribution by Pipeline Maturity
  • Figure 9.5 Startup-Health Indexing: Distribution by Financial Investment
  • Figure 9.6 Startup-Health Indexing: Distribution by Partnership Activity
  • Figure 9.7 Startup-Health Indexing: Roots Analysis Perspective
  • Figure 9.8 Spider Web Analysis: Leading Companies
  • Figure 10.1 Global Therapeutic Vaccines Market, 2022-2035 (USD Million)
  • Figure 10.2 Global Therapeutic Vaccines Market: Distribution by Type of Vaccine, 2022-2035
  • Figure 10.3 Global Therapeutic Vaccines Market: Distribution by Method of Vaccine Composition, 2022-2035
  • Figure 10.4 Global Therapeutic Vaccines Market: Distribution by Type of Therapy, 2022-2035
  • Figure 10.5 Global Therapeutic Vaccines Market: Distribution by Target Disease Indication, 2022-2035
  • Figure 10.6 Global Therapeutic Vaccines Market: Distribution by Route of Administration, 2022-2035
  • Figure 10.7 Therapeutic Vaccines Market in US, 2022-2035
  • Figure 10.8 Therapeutic Vaccines Market in Canada, 2022-2035
  • Figure 10.9 Therapeutic Vaccines Market in UK, 2022-2035
  • Figure 10.10 Therapeutic Vaccines Market in Germany, 2022-2035
  • Figure 10.11 Therapeutic Vaccines Market in France, 2022-2035
  • Figure 10.12 Therapeutic Vaccines Market in Italy, 2022-2035
  • Figure 10.13 Therapeutic Vaccines Market in Spain, 2022-2035
  • Figure 10.14 Therapeutic Vaccines Market in Australia, 2022-2035
  • Figure 10.15 Therapeutic Vaccines Market in Japan, 2022-2035
  • Figure 10.16 Therapeutic Vaccines Market in Korea, 2022-2035
  • Figure 10.17 Therapeutic Vaccines Market in Brazil, 2022-2035
  • Figure 10.18 Therapeutic Vaccines Market in Israel, 2022-2035
  • Figure 10.19 ASP0113 (Astellas Pharma): Estimated Sales, 2022-2035 (USD Million)
  • Figure 10.20 Copaxone (Teva Pharmaceuticals): Estimated Sales, 2022-2035 (USD Million)
  • Figure 10.21 Galinpeptimut-S (Sellas Life Sciences): Estimated Sales, 2024-2035 (USD Million)
  • Figure 10.22 Hepcortespenlisimut-L (Immunitor): Estimated Sales, 2022-2035 (USD Million)
  • Figure 10.23 ICT-107 (Precision Life Sciences): Estimated Sales, 2022-2035 (USD Million)
  • Figure 10.24 IR103 (Immune Response Biopharma): Estimated Sales, 2022-2035 (USD Million)
  • Figure 10.25 MGN1703 (Mologen): Estimated Sales, 2022-2035 (USD Million)
  • Figure 10.26 Neuronata-R (OptiNose): Estimated Sales, 2027-2035 (USD Million)
  • Figure 10.27 OncoVax (Corestem): Estimated Sales, 2023-2035 (USD Million)
  • Figure 10.28 OSE2101 (OSE Immunotherapeutics): Estimated Sales, 2022-2035 (USD Million)
  • Figure 10.29 Provenge (Dendreon Pharmaceuticals): Estimated Sales, 2022-2035 (USD Million)
  • Figure 10.30 REMUNE (Immune Response Biopharma): Estimated Sales, 2022-2035 (USD Million)
  • Figure 10.31 RIAVAX (Kael-GemVax): Estimated Sales, 2024-2035 (USD Million)
  • Figure 10.32 V503 (Merck): Estimated Sales, 2027-2035 (USD Million)
  • Figure 10.33 V7 (Immunitor): Estimated Sales, 2022-2035 (USD Million)
  • Figure 10.34 VGX-3100 (Inovio Pharmaceuticals): Estimated Sales, 2023-2035 (USD Million)
  • Figure 10.35 Vigil (Gradalis): Estimated Sales, 2025-2035 (USD Million)
  • Figure 11.1 Clinical-Stage Preventive Vaccines: Distribution by Phase of Development
  • Figure 11.2 Clinical-Stage Preventive Vaccines: Distribution by Route of Administration
  • Figure 11.3 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API
  • Figure 11.4 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API and Phase of Development
  • Figure 11.5 Clinical-Stage Preventive Vaccines: Distribution by Dosage Form
  • Figure 11.6 Clinical-Stage Preventive Vaccines: Distribution by Target Disease Indication
  • Figure 11.7 Key Industry Players: Distribution by Number of Vaccines in Clinical Development
  • Figure 11.8 Key Non-Industry Players: Distribution by Number of Vaccines in Clinical Development
  • Figure 12.1 Vaccine CMOs: Distribution by Year of Establishment
  • Figure 12.2 Vaccine CMOs: Distribution by Company Size and Geographical Location
  • Figure 12.3 World Map Representation: Distribution by Geography
  • Figure 12.4 Vaccine CMOs: Distribution by Types of Service(s) Offered
  • Figure 12.5 Vaccine CMOs: Distribution by Additional Services Offered and Location of Headquarters
  • Figure 12.6 Vaccine CMOs: Distribution by Scale of Operation
  • Figure 12.7 Vaccine CMOs: Distribution by Type of Expression System(s) Used
  • Figure 12.8 Vaccine CMOs: Distribution by Type of Vaccine Manufactured
  • Figure 13.1 Concluding Remarks: Overall Market Landscape
  • Figure 13.2 Concluding Remarks: Clinical Trial Analysis
  • Figure 13.3 Concluding Remarks: Academic Grant Analysis
  • Figure 13.4 Concluding Remarks: Partnerships and Collaborations
  • Figure 13.5 Concluding Remarks: Start-up Health Indexing
  • Figure 13.6 Concluding Remarks: Market Forecast

List OfTables

  • Table 3.1 Vaccines for Cancer Treatment
  • Table 3.2 Vaccines for HIV Treatment
  • Table 3.3 Vaccines for HPV Treatment
  • Table 3.4 Vaccines for Herpes Treatment
  • Table 4.1 List of Therapeutic Vaccines
  • Table 5.1 Global Therapeutic Vaccines: List of Companies Profiled
  • Table 5.2 BioNTech: Company Snapshot
  • Table 5.3 Vaccine Profile: BNT-111
  • Table 5.4 Vaccine Profile: BNT-112
  • Table 5.5 Vaccine Profile: BNT-113
  • Table 5.6 Vaccine Profile: BNT-115
  • Table 5.7 Vaccine Profile: BNT-116
  • Table 5.8 Vaccine Profile: BNT-122
  • Table 5.9 Vaccine Profile: W_pro1
  • Table 5.10 Vaccine Profile: HPV Vaccine
  • Table 5.11 Vaccine Profile: IVAC MUTANOME
  • Table 5.12 Vaccine Profile: RBL001/RBL002
  • Table 5.13 Vaccine Profile: NEO-PV-01
  • Table 5.14 BioNTech: Recent Developments and Future Outlook
  • Table 5.15 Brii Biosciences: Company Snapshot
  • Table 5.16 Vaccine Profile: Bri-179
  • Table 5.17 Vaccine Profile: Bri-835
  • Table 5.18 Vaccine Profile: Bri-778
  • Table 5.19 Vaccine Profile: Bri-732
  • Table 5.20 Vaccine Profile: Bri-296
  • Table 5.21 Brii Biosciences: Recent Developments and Future Outlook
  • Table 5.22 GlobeImmune: Company Snapshot
  • Table 5.23 Vaccine Profile: GI-6301
  • Table 5.24 Vaccine Profile: GI-6207
  • Table 5.25 Vaccine Profile: GI-4000
  • Table 5.26 Vaccine Profile: GS-4774
  • Table 5.27 Vaccine Profile: GI-5005
  • Table 5.28 GlobeImmune: Recent Developments and Future Outlook
  • Table 5.29 Immatics: Company Snapshot
  • Table 5.30 Vaccine Profile: APVAC
  • Table 5.31 Vaccine Profile: IMA901
  • Table 5.32 Vaccine Profile: IMA910
  • Table 5.33 Vaccine Profile: IMA950
  • Table 5.34 Vaccine Profile: IMA970A
  • Table 5.35 Immatics: Recent Developments and Future Outlook
  • Table 5.36 Immune Response Biopharma: Company Snapshot
  • Table 5.37 Vaccine Profile: IR103
  • Table 5.38 Vaccine Profile: REMUNE
  • Table 5.39 Vaccine Profile: NeuroVax
  • Table 5.40 Vaccine Profile: RAVAX
  • Table 5.41 Vaccine Profile: Zorcell
  • Table 5.42 Immune Response Biopharma: Recent Developments and Future Outlook
  • Table 5.43 Immunitor: Company Snapshot
  • Table 5.44 Vaccine Profile: Atherosclerosis Vaccine
  • Table 5.45 Vaccine Profile: V3-MOMMO
  • Table 5.46 Vaccine Profile: Hepcortespenlisimut-L
  • Table 5.47 Vaccine Profile: V-Boost
  • Table 5.48 Vaccine Profile: V3-OVA
  • Table 5.49 Vaccine Profile: V3-Myoma
  • Table 5.50 Vaccine Profile: V3-Cervix
  • Table 5.51 Vaccine Profile: V7
  • Table 5.52 Vaccine Profile: V3-X
  • Table 5.53 Vaccine Profile: V3-P
  • Table 5.54 Vaccine Profile: V-Endo
  • Table 5.55 Vaccine Profile: V8
  • Table 5.56 Vaccine Profile: V-SARS
  • Table 5.57 Immunitor: Recent Developments and Future Outlook
  • Table 5.58 Innovio Pharmaceuticals: Company Snapshot
  • Table 5.59 Vaccine Profile: VGX-3100
  • Table 5.60 Vaccine Profile: INO-3107
  • Table 5.61 Vaccine Profile: INO-5401
  • Table 5.62 Vaccine Profile: INO-5151
  • Table 5.63 Vaccine Profile: INO-3112
  • Table 5.64 Vaccine Profile: INO-5150
  • Table 5.65 Vaccine Profile: INO-3106
  • Table 5.66 Vaccine Profile: INO-1800
  • Table 5.67 Innovio Pharmaceuticals: Recent Developments and Future Outlook
  • Table 5.68 Moderna: Company Snapshot
  • Table 5.69 Vaccine Profile: mRNA-4157
  • Table 5.70 Vaccine Profile: mRNA-3927
  • Table 5.71 Vaccine Profile: mRNA-3705
  • Table 5.72 Vaccine Profile: mRNA-3745
  • Table 5.73 Vaccine Profile: mRNA-5671
  • Table 5.74 Vaccine Profile: mRNA-2752
  • Table 5.75 Moderna: Recent Developments and Future Outlook
  • Table 8.1 Global Therapeutic Vaccines: List of Partnerships and Collaborations, 2016-2022
  • Table 9.1 Therapeutic Vaccines Start-ups: Distribution by Location of Headquarters
  • Table 10.1 Global Therapeutic Vaccines: Summary of the Competitive Insights
  • Table 11.1 List of Marketed Preventive Vaccines
  • Table 11.2 List of Clinical-Stage Preventive Vaccines
  • Table 12.1 Vaccine Contract Manufacturers: List of Service Providers
  • Table 12.2 Vaccine CMOs: Information on Type of Service(s) Offered
  • Table 12.3 Vaccine CMOs: Information on Scale of Operation
  • Table 12.4 Vaccine CMOs: Information on Type of Expression System(s) Used
  • Table 12.5 Vaccine CMOs: Information on Type of Vaccines Manufactured
  • Table 14.1 Therapeutic Vaccines: Distribution by Phase of Development
  • Table 14.2 Therapeutic Vaccines: Distribution by Type of Vaccine
  • Table 14.3 Therapeutic Vaccines: Distribution by Type of Vaccine (by Method of Composition)
  • Table 14.4 Therapeutic Vaccines: Distribution by Type of Therapy
  • Table 14.5 Therapeutic Vaccines: Distribution by Target Disease Indication
  • Table 14.6 Therapeutic Vaccines: Distribution by Route of Administration
  • Table 14.7 Therapeutic Vaccines: Distribution by Dosage
  • Table 14.8 Therapeutic Vaccines Developers: Distribution by Type of Developers
  • Table 14.9 Therapeutic Vaccines Developers: Distribution by Year of Establishment
  • Table 14.10 Therapeutic Vaccines Developers: Distribution by Company Size
  • Table 14.11 Therapeutic Vaccines Developers: Distribution by Location of Headquarters
  • Table 14.12 Leading Developers
  • Table 14.13 Grid Analysis: Distribution by Phase of Development, Company Size and Location of Headquarters
  • Table 14.14 BioNTech: Annual Revenues, 2016-2021 (USD Million)
  • Table 14.15 Brii Biosciences: Annual Revenues, 2016-2021 (USD Million)
  • Table 14.16 GlobeImmune: Annual Revenues, 2016-2021 (USD Million)
  • Table 14.17 Immatics: Annual Revenues, 2016-2021 (USD Million)
  • Table 14.18 Immune Response Biopharma: Annual Revenues, 2016-2021 (USD Million)
  • Table 14.19 Inovio Pharmaceuticals: Annual Revenues, 2016-2021 (USD Million)
  • Table 14.20 Moderna: Annual Revenues, 2016-2021 (USD Million)
  • Table 14.21 Clinical Trial Analysis: Scope and Methodology
  • Table 14.22 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2010-2022
  • Table 14.23 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2010-2022
  • Table 14.24 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 14.25 Clinical Trial Analysis: Distribution by Trial Recruitment Status
  • Table 14.26 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
  • Table 14.27 Clinical Trial Analysis: Distribution by Study Design
  • Table 14.28 Clinical Trial Analysis: Distribution by Trial Focus Area
  • Table 14.29 Clinical Trial Analysis: Distribution by Target Disease Indication
  • Table 14.30 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 14.31 Most Active Players: Distribution by Number of Registered Trials
  • Table 14.32 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
  • Table 14.33 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
  • Table 14.34 Grant Analysis: Cumulative Year-wise Trend, 2016-2022
  • Table 14.35 Grant Analysis: Cumulative Distribution by Amount Awarded (USD Million) 2016-2022
  • Table 14.36 Grant Analysis: Distribution by Administering Institute Center
  • Table 14.37 Grant Analysis: Distribution by Support Period
  • Table 14.38 Grant Analysis: Distribution by Administering Institute Center and Support Period
  • Table 14.39 Grant Analysis: Distribution by Type of Grant Application
  • Table 14.40 Grant Analysis: Distribution by Purpose of Grant Award
  • Table 14.41 Grant Analysis: Distribution by Activity Code
  • Table 14.42 Grant Analysis: Distribution by Study Section Involved
  • Table 14.43 Grant Analysis: Distribution by Type of Recipient Organization
  • Table 14.44 Grant Analysis: Geographical Distribution of Recipient Organizations
  • Table 14.45 Popular NIH Departments: Distribution by Number of Grants
  • Table 14.46 Prominent Program Officers: Distribution by Number of Grants
  • Table 14.47 Popular Recipient Organizations: Distribution by Number of Grants
  • Table 14.48 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2022
  • Table 14.49 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 14.50 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
  • Table 14.51 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
  • Table 14.52 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Table 14.53 Partnerships and Collaborations: Distribution by Therapeutic Area
  • Table 14.54 Most Active Players: Distribution by Number of Partnerships
  • Table 14.55 Partnerships and Collaborations: Regional Distribution
  • Table 14.56 Startup-Health Indexing: Distribution by Location of Headquarters
  • Table 14.57 Startup-Health Indexing: Distribution by Supplier Strength
  • Table 14.58 Startup-Health Indexing: Distribution by Pipeline Strength
  • Table 14.59 Startup-Health Indexing: Distribution by Pipeline Maturity
  • Table 14.60 Startup-Health Indexing: Distribution by Financial Investment
  • Table 14.61 Startup-Health Indexing: Distribution by Partnership Activity
  • Table 14.62 Startup-Health Indexing: Roots Analysis Perspective
  • Table 14.63 Global Therapeutic Vaccines Market, 2022-2035 (USD Million)
  • Table 14.64 Global Therapeutic Vaccines Market: Distribution by Type of Vaccine, 2022-2035
  • Table 14.65 Global Therapeutic Vaccines Market: Distribution by Method of Vaccine Composition, 2022-2035
  • Table 14.66 Global Therapeutic Vaccines Market: Distribution by Type of Therapy, 2022-2035
  • Table 14.67 Global Therapeutic Vaccines Market: Distribution by Target Disease Indication, 2022-2035
  • Table 14.68 Global Therapeutic Vaccines Market: Distribution by Route of Administration, 2022-2035
  • Table 14.69 Therapeutic Vaccines Market in US, 2022-2035
  • Table 14.70 Therapeutic Vaccines Market in Canada, 2022-2035
  • Table 14.71 Therapeutic Vaccines Market in UK, 2022-2035
  • Table 14.72 Therapeutic Vaccines Market in Germany, 2022-2035
  • Table 14.73 Therapeutic Vaccines Market in France, 2022-2035
  • Table 14.74 Therapeutic Vaccines Market in Italy, 2022-2035
  • Table 14.75 Therapeutic Vaccines Market in Spain, 2022-2035
  • Table 14.76 Therapeutic Vaccines Market in Australia, 2022-2035
  • Table 14.77 Therapeutic Vaccines Market in Japan, 2022-2035
  • Table 14.78 Therapeutic Vaccines Market in Korea, 2022-2035
  • Table 14.79 Therapeutic Vaccines Market in Brazil, 2022-2035
  • Table 14.80 Therapeutic Vaccines Market in Israel, 2022-2035
  • Table 14.81 ASP0113 (Astellas Pharma): Estimated Sales, 2022-2035 (USD Million)
  • Table 14.82 Copaxone (Teva Pharmaceuticals): Estimated Sales, 2022-2035 (USD Million)
  • Table 14.83 Galinpeptimut-S (Sellas Life Sciences): Estimated Sales, 2024-2035 (USD Million)
  • Table 14.84 Hepcortespenlisimut-L (Immunitor): Estimated Sales, 2022-2035 (USD Million)
  • Table 14.85 ICT-107 (Precision Life Sciences): Estimated Sales, 2022-2035 (USD Million)
  • Table 14.86 IR103 (Immune Response Biopharma): Estimated Sales, 2022-2035 (USD Million)
  • Table 14.87 MGN1703 (Mologen): Estimated Sales, 2022-2035 (USD Million)
  • Table 14.88 Neuronata-R (OptiNose): Estimated Sales, 2027-2035 (USD Million)
  • Table 14.89 OncoVax (Corestem): Estimated Sales, 2023-2035 (USD Million)
  • Table 14.90 OSE2101 (OSE Immunotherapeutics): Estimated Sales, 2022-2035 (USD Million)
  • Table 14.91 Provenge (Dendreon Pharmaceuticals): Estimated Sales, 2022-2035 (USD Million)
  • Table 14.92 REMUNE (Immune Response Biopharma): Estimated Sales, 2022-2035 (USD Million)
  • Table 14.93 RIAVAX (Kael-GemVax): Estimated Sales, 2024-2035 (USD Million)
  • Table 14.94 V503 (Merck): Estimated Sales, 2027-2035 (USD Million)
  • Table 14.95 V7 (Immunitor): Estimated Sales, 2022-2035 (USD Million)
  • Table 14.96 VGX-3100 (Inovio Pharmaceuticals): Estimated Sales, 2023-2035 (USD Million)
  • Table 14.97 Vigil (Gradalis): Estimated Sales, 2025-2035 (USD Million)
  • Table 14.98 Clinical-Stage Preventive Vaccines: Distribution by Phase of Development
  • Table 14.99 Clinical-Stage Preventive Vaccines: Distribution by Route of Administration
  • Table 14.100 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API
  • Table 14.101 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API and Phase of Development
  • Table 14.102 Clinical-Stage Preventive Vaccines: Distribution by Dosage Form
  • Table 14.103 Clinical-Stage Preventive Vaccines: Distribution by Target Disease Indication
  • Table 14.104 Key Industry Players: Distribution by Number of Vaccines in Clinical Development
  • Table 14.105 Key Non-Industry Players: Distribution by Number of Vaccines in Clinical Development
  • Table 14.106 Vaccine CMOs: Distribution by Year of Establishment
  • Table 14.107 Vaccine CMOs: Distribution by Company Size and Geographical Location
  • Table 14.108 Vaccine CMOs: Distribution by Types of Service(s) Offered
  • Table 14.109 Vaccine CMOs: Distribution by Additional Services Offered and Location of Headquarters
  • Table 14.110 Vaccine CMOs: Distribution by Scale of Operation
  • Table 14.111 Vaccine CMOs: Distribution by Type of Expression System(s) Used
  • Table 14.112 Vaccine CMOs: Distribution by Type of Vaccine Manufactured

List OfCompanies

The following companies and organizations have been mentioned in the report:

  • 1. 3D Medicines
  • 2. Abivax
  • 3. AC Immune
  • 4. Adaptive Biotechnologies
  • 5. Aduro Biotech
  • 6. Advaxis
  • 7. AFFiRiS
  • 8. Altimmune
  • 9. ApolloBio
  • 10. Arbutus Biopharma
  • 11. Archivel Farma
  • 12. Argos Therapeutics
  • 13. Astellas Pharma
  • 14. Aston Sci.
  • 15. AstraZeneca
  • 16. AVAX Technologies
  • 17. Axon Neuroscience
  • 18. Bavarian Nordic
  • 19. Beijing Genomics Institute
  • 20. Bellicum Pharmaceuticals
  • 21. Bionor Immuno
  • 22. BioNTech
  • 23. Biosantech
  • 24. Brii Biosciences
  • 25. Bristol Myers Squibb
  • 26. Cancer Insight
  • 27. Cancer Vaccines
  • 28. Chinook Therapeutics
  • 29. Chongqing Jiachen Biotechnology
  • 30. Corestem
  • 31. CuraVac
  • 32. Cure&Sure Biotech
  • 33. CureVac
  • 34. CYTLIMIC
  • 35. Dana-Farber Cancer Institute
  • 36. DCPrime
  • 37. Dendreon Pharmaceuticals
  • 38. Dynavax Technologies
  • 39. EMD Serono
  • 40. Enterome
  • 41. Epimmune
  • 42. eTheRNA immunotherapies
  • 43. European Oncology Clinical Trial Group
  • 44. European Network of Gynaecological Oncological Trial Groups (ENGOT)
  • 45. FIT Biotech
  • 46. Frame Therapeutics
  • 47. Frontier Biotechnologies
  • 48. Galena Biopharma
  • 49. GeneCure Biotechnologies
  • 50. Genentech
  • 51. Geneos Therapeutics
  • 52. Genexine
  • 53. Genocea Biosciences
  • 54. Genticel
  • 55. Gilead Sciences
  • 56. GlaxoSmithKline
  • 57. GlobeImmune
  • 58. Gradalis
  • 59. Gritstone bio
  • 60. Hangzhou Neoantigen Therapeutics
  • 61. Helocyte
  • 62. Ichor Medical Systems
  • 63. Immatics Biotechnologies
  • 64. Immune Design
  • 65. Immune Response BioPharma
  • 66. Immunicum
  • 67. Immunitor
  • 68. ImmunityBio
  • 69. ImmunoCellular Therapeutics
  • 70. Immunomic Therapeutics
  • 71. Immunor
  • 72. ImmunoVaccine Technologies
  • 73. Immunovative Therapies
  • 74. ImmusanT
  • 75. Immutep
  • 76. Incyte
  • 77. InnaVirVax
  • 78. Inovio Pharmaceuticals
  • 79. Invectys
  • 80. iOncologi
  • 81. ISA Pharmaceuticals
  • 82. Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson)
  • 83. Janssen Vaccines & Prevention (a subsidiary of Johnson & Johnson)
  • 84. GemVax & KAEL
  • 85. Kun Tuo
  • 86. Laboratorios Silanes
  • 87. LG Life Sciences
  • 88. Eli Lilly
  • 89. MabVax Therapeutics
  • 90. Madison Vaccines
  • 91. Marker Therapeutics
  • 92. Medigene
  • 93. MedImmune
  • 94. Memorial Sloan Kettering Cancer Center
  • 95. Merck
  • 96. Ministry of Health and Family Welfare (MoHFW)
  • 97. Moderna
  • 98. MOLOGEN
  • 99. Morphogenesis
  • 100. Mymetics
  • 101. NantBioScience (a subsidiary of NantWorks)
  • 102. National Heart, Lung, and Blood Institute (NHLBI)
  • 103. NEC OncoImmunity
  • 104. Nektar Therapeutics
  • 105. NewLink Genetics
  • 106. Nobelpharma
  • 107. Nordic Society of Gynaecological Oncology (NSGO)
  • 108. Nouscom
  • 109. Novartis Pharmaceuticals
  • 110. NovaRx
  • 111. NuGenerex Immuno-Oncology
  • 112. Nykode Therapeutics
  • 113. OncBioMune Pharmaceuticals
  • 114. OncoPep
  • 115. OncoTherapy Science
  • 116. Origimm Biotechnology (acquired by Sanofi)
  • 117. OSE Immunotherapeutics
  • 118. Oxford Vacmedix
  • 119. PapiVax Biotech
  • 120. Parker Institute for Cancer Immunotherapy
  • 121. PCI Biotech
  • 122. PDC*line Pharma
  • 123. Peptinov
  • 124. Pfizer
  • 125. Precision BioSciences
  • 126. Precision Life Sciences
  • 127. Profectus BioSciences
  • 128. QIAGEN
  • 129. Quantoom Biosciences
  • 130. Regeneron Pharmaceuticals
  • 131. ReiThera
  • 132. Replicate Bioscience
  • 133. RhoVac
  • 134. Rigontec (acquired by Merck)
  • 135. ROVI Pharmaceuticals
  • 136. Sanofi
  • 137. SciVac Therapeutics
  • 138. Selecta Biosciences
  • 139. SELLAS Life Sciences
  • 140. Shenzhen BioScien Pharmaceuticals
  • 141. Stemirna Therapeutics
  • 142. Stemline Therapeutics
  • 143. Teva Pharmaceuticals
  • 144. Themis Medicare
  • 145. Thyas
  • 146. Translate Bio (acquired by Sanofi)
  • 147. UConn Health
  • 148. Ultimovacs
  • 149. University of Oxford
  • 150. University of Pennsylvania
  • 151. Vaccinogen
  • 152. Vaccitech
  • 153. VaxEquity
  • 154. VAXIMM
  • 155. Vaxine
  • 156. VAXON Biotech
  • 157. VBI Vaccines
  • 158. Vertex
  • 159. Vical
  • 160. ViciniVax
  • 161. Wistar Institute
  • 162. XEME Biopharma